Redefining Interventional Therapy for Severely Calcified Lesions
AVS is an early-stage medical device company that is focused on safely and effectively treating severely calcified arterial disease. AVS is the first company to develop pulsatile intravascular lithotripsy (PIVL), a therapy that is delivered through a balloon-based platform called the Pulse IVL System. It is designed to be the only minimally invasive technology that gently shatters calcium and opens the artery using a single device.
Our Journey
-
2017
Image
- Company founded by clinical and engineering team from University of Michigan
- Proof of concept developed
-
2018
Image
- Grant support received from NIH/Cleveland Clinic and U of M Fast Forward Medical Innovation
-
2019
Image
- Completion of successful animal study for safety
- Performed early cadaver study with positive results
- Patents filed with US Patents & Trademark Office
-
2020
Image
- Secured funding from visionary healthcare investment firm
- Hired management team
-
2021
Image
- Built peripheral product
- Completed cadaver studies with positive results confirmed by Renu Virmani
- TCT Shark Tank Innovation finalist
-
2022
Image
- First patent granted
- Successfully performed first in human cases
- Initiated product development for coronary indication
-
2023
Image
- Raised $28 Million in Series B Round
- Relocated corporate office to Boston, MA seaport area
Image
“We are proud to have been selected as a FINALIST in the CRF Shark Tank Innovation Competition”